NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vector Group Ltd. VGR, NovoCure Limited NVCR, ORBCOMM Inc. ORBC, Adamis Pharmaceuticals Corporation ADMP, Calumet Specialty Products Partners, L.P. CLMT, and Lakeland Bancorp, Inc. LBAI, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
VGR DOWNLOAD: http://Fundamental-Markets.com/register/?so=VGR
NVCR DOWNLOAD: http://Fundamental-Markets.com/register/?so=NVCR
ORBC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ORBC
ADMP DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADMP
CLMT DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLMT
LBAI DOWNLOAD: http://Fundamental-Markets.com/register/?so=LBAI
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Vector Group Ltd. VGR, NovoCure Limited NVCR, ORBCOMM Inc. ORBC, Adamis Pharmaceuticals Corporation ADMP, Calumet Specialty Products Partners, L.P. CLMT, and Lakeland Bancorp, Inc. LBAI on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 7th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
Vector Group Ltd. (VGR) REPORT OVERVIEW
Vector Group's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Vector Group reported revenue of $484.63MM vs $459.10MM (up 5.56%) and basic earnings per share $0.13 vs $0.17 (down 23.53%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Vector Group reported revenue of $1,690.95MM vs $1,657.20MM (up 2.04%) and basic earnings per share $0.53 vs $0.44 (up 21.73%). Vector Group is expected to report earnings on March 1st, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.12. The estimated EPS forecast for the next fiscal year is $0.66 and is expected to report on March 1st, 2018.
To read the full Vector Group Ltd. (VGR) report, download it here: http://Fundamental-Markets.com/register/?so=VGR
-----------------------------------------
NovoCure Limited (NVCR) REPORT OVERVIEW
NovoCure's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, NovoCure reported revenue of $50.11MM vs $21.67MM (up 131.19%) and basic earnings per share -$0.13 vs -$0.39. For the twelve months ended December 31st, 2016 vs December 31st, 2015, NovoCure reported revenue of $82.89MM vs $33.09MM (up 150.52%) and basic earnings per share -$1.54 vs -$3.67. NovoCure is expected to report earnings on February 22nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is -$0.36 and is expected to report on February 22nd, 2018.
To read the full NovoCure Limited (NVCR) report, download it here: http://Fundamental-Markets.com/register/?so=NVCR
-----------------------------------------
ORBCOMM Inc. (ORBC) REPORT OVERVIEW
ORBCOMM's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, ORBCOMM reported revenue of $69.37MM vs $46.29MM (up 49.86%) and basic earnings per share -$0.54 vs -$0.20. For the twelve months ended December 31st, 2016 vs December 31st, 2015, ORBCOMM reported revenue of $186.74MM vs $178.29MM (up 4.74%) and basic earnings per share -$0.33 vs -$0.19. ORBCOMM is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is -$0.14 and is expected to report on February 27th, 2018.
To read the full ORBCOMM Inc. (ORBC) report, download it here: http://Fundamental-Markets.com/register/?so=ORBC
-----------------------------------------
Adamis Pharmaceuticals Corporation (ADMP) REPORT OVERVIEW
Adamis Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Adamis Pharmaceuticals reported revenue of $3.39MM vs $2.08MM (up 63.22%) and basic earnings per share -$0.21 vs -$0.41. Adamis Pharmaceuticals is expected to report earnings on March 29th, 2018. The report will be for the fiscal period ending December 31st, 2017. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on March 29th, 2018.
To read the full Adamis Pharmaceuticals Corporation (ADMP) report, download it here: http://Fundamental-Markets.com/register/?so=ADMP
-----------------------------------------
Calumet Specialty Products Partners, L.P. (CLMT) REPORT OVERVIEW
Calumet Specialty Products Partners' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Calumet Specialty Products Partners reported revenue of $1,097.40MM vs $966.60MM (up 13.53%) and basic earnings per share -$0.30 vs -$0.42. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Calumet Specialty Products Partners reported revenue of $3,599.40MM vs $4,212.80MM (down 14.56%) and basic earnings per share -$4.18 vs -$2.05. Calumet Specialty Products Partners is expected to report earnings on February 23rd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.98. The estimated EPS forecast for the next fiscal year is -$0.95 and is expected to report on February 23rd, 2018.
To read the full Calumet Specialty Products Partners, L.P. (CLMT) report, download it here: http://Fundamental-Markets.com/register/?so=CLMT
-----------------------------------------
Lakeland Bancorp, Inc. (LBAI) REPORT OVERVIEW
Lakeland's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Lakeland reported interest income of $48.74MM vs $43.01MM (up 13.32%) and basic earnings per share $0.29 vs $0.25 (up 16.00%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Lakeland reported interest income of $163.30MM vs $127.51MM (up 28.06%) and basic earnings per share $0.96 vs $0.85 (up 12.94%). Lakeland is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.26. The estimated EPS forecast for the next fiscal year is $1.46 and is expected to report on January 25th, 2019.
To read the full Lakeland Bancorp, Inc. (LBAI) report, download it here: http://Fundamental-Markets.com/register/?so=LBAI
-----------------------------------------
ABOUT Fundamental Markets
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
